{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
NCT03799341: Not Applicable Interventional Active, not recruiting Cocaine Use Disorder
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Acetamiprid is a carboxamidine that is acetamidine in which the amino hydrogens are substituted by a (6-chloropyridin-3-yl)methyl and a methyl group while the hydrogen attached to the imino nitrogen is replaced by a cyano group. It has a role as a neonicotinoid insectide, an environmental contaminant and a xenobiotic. It is a monochloropyridine, a nitrile and a carboxamidine. It derives from a 2-chloropyridine. Acetamiprid is an insecticide that is currently approved for EU use. It is highly soluble in water and is volatile. Based on its chemical properties it would not be expected to leach to groundwater. It is not persistence in soil systems but may be very persistent in aquatic systems under certain conditions. It has a moderate mammalian toxicity and it has a high potential for bioaccumulation. Acetamiprid is a recognised irritant. It is highly toxic to birds and earthworms and moderately toxic to most aquatic organisms. Acetamiprid is a nicotinic agonist that reacts with nicotinic acetylcholine receptors (nACh-R). The activation of the nACh-R receptors causes hyperactivity and muscle spasms, and eventually death.
Status:
Investigational
Source:
NCT00758303: Phase 2/Phase 3 Interventional Completed Hyperlipidemia
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Trigonellamide (1-Methylnicotinamide) is a metabolite of nicotinamide and is produced primarily in the liver by nicotinamide N-methyltransferase. Trigonellamide may be an endogenous activator of prostacyclin (PGI2) production and thus may regulate thrombotic as well as inflammatory processes in the cardiovascular system. The mechanisms of action of Trigonellamide involve the activation of PGI2 release driven by cyclooxygenase 2 (COX-2). PGI2 releasing capacity of 1- Trigonellamide was shown to afford not only anti-thrombotic but also fibrinolytic, anti-inflammatory and gastroprotective effects. Interestingly, Trigonellamide did not directly either affect the activity of leucocytes or release PGI2 in the perfused rat hindquarters model. Still, Trigonellamide, due to its PGI2 releasing capacity, might serve as a hepatoprotective agent that protects against Concanavalin-A induced liver injury through the downregulation of interleukin-4 (IL-4) and tumor necrosis factor-α signalization (TNF-α). In addition to its anti-platelet, anti-thrombotic and anti-inflammatory activities, 1-MNA has also been shown to restore endothelial function in diabetic hyperglycemic rats, as well as to improve endothelial function in humans. PGI2 displays anti-metastatic activity, and the PGI2 releasing activity of Trigonellamide, the potential application of exogenous Trigonellamide to prevent metastatic cancer.
Class (Stereo):
CHEMICAL (MIXED)
Pentapiperide is an anticholinergic drug with antisecretory and antimotility activity on the upper gastrointestinal tract, which was used as adjunctive therapy for relieving the symptoms of peptic ulcer. pentapiperide methylsulfate) has approximately the same in vitro antispasmodic activity as atropine. In vivo, however, the quaternary ammonium compounds such as pentapiperide methylsulfate are less readily absorbed from the gastrointestinal tract than are the tertiary amines such as atropine. Pentapiperide methylsulfate is contraindicated in patients with glaucoma or a predisposition to glaucoma, in patients with pyloric obstruction or stenosis, gastric retention, known or suspected obstructive disease of the gastrointestinal tract, and urinary bladder neck obstruction. It is also contraindicated in prostatic hypertrophy, stenosing peptic ulcer, megaesophagus, organic cardiospasm, and in patients with a hypersensitivity to the drug. Xerostomia was the most frequently encountered complaint. In decreasing order of frequency, visual blurring, difficult micturition, constipation, and nausea were reported.
Status:
Investigational
Source:
USAN:QUINTERENOL SULFATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT01827605: Phase 3 Interventional Active, not recruiting Relapsed Follicular Lymphoma
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tricyclazole is a systemic fungicide for control of Pyricularia oryzae on rice. Tricyclazole protects plants from infection by P. oryzae by preventing penetration of the epidermis by the fungus. The compound acts by inhibiting melanization within the appressorium, thus causing a lack of rigidity in the appressorial wall. Tricyclazole has no apparent effect on spore germination although sporulation is reduced. Tricyclazole is not curative but is protective in its activity. Tricyclazole can influence the pathogenic ability of aspergillus aculeatus by damaging the cell structure of hyphae and conidia, reducing the melanin production, and altering the expression of pathogenic-related gene. Tricyclazole toxin can impair testosterone secretion and the testicular structure in mice, leaving an adversely effect on sperm production system.
Status:
Investigational
Source:
USAN:TICABESONE PROPIONATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ticabesone Propionate is Ticabesone ester patented by Syntex, Inc. as an anti-inflammatory agent. Ticabesone Propionate shows potent antiinflammatory activity silver nitrate-induced inflammation in the rat cornea.
Status:
Investigational
Source:
NCT02275403: Phase 2 Interventional Completed Breast Cancer
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00002914: Phase 2 Interventional Completed Bladder Cancer
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Piritrexim is a synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase, thereby disrupting folate metabolism and DNA synthesis and cell division. A theoretical advantage of piritrexim over trimetrexate is a lack of any known effects on histamine metabolism, which may lower the risk of hypersensitivity reactions. Piritrexim is a nonclassical antifolate for antitumor and parasitic chemotherapy that passively diffuses into cells and hence do not have to depend on folylpoly-gamma-glutamate synthetase or the reduced folate carrier. Because piritrexim is not a substrate for polyglutamation, the drug is not selectively retained within cells for prolonged periods. Piritrexim has a reliably high oral bioavailability of about 75%, which has led to its development as an oral lipophilic antifolate. Most commonly, it has been administered in oral daily doses of 75 to 150 mg bid or tid every 5 days, with cycles repeated every 3 weeks. Oral absorption is rapid, with peak plasma levels appearing at 1.5 hours after ingestion. Elimination occurs primarily via hepatic metabolism of the drug to active metabolites, and the terminal half-life of the parent compound is about 1.5 to 4.5 hours. Single-agent oral piritrexim has clinical activity in melanoma, urothelial cancers, and head and neck cancers. Tolerable combinations of piritrexim with cisplatin, fluorouracil, and leucovorin have been tested, with promising results achieved in head and neck cancer. An interesting attempt to alternate piritrexim with methotrexate did not have any greater activity than methotrexate alone.
Status:
Investigational
Source:
NCT02149238: Not Applicable Interventional Completed Cardiovascular Diseases
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
7-Methylxanthine is a methyl derivative of xanthine, found occasionally in human urine. 7-Methylxanthine is one of the purine components in urinary calculi. 7-methylxanthine (7-MX) is a metabolite of caffeine and theobromine, and has been shown to have low toxicity and no carcinogenic effects. 7-MX is known as a non-selective adenosine antagonist and has been shown to work against myopia. 7-MX has little effect on the proliferation or apoptosis of human RPE cells; however, 7-MX disturbs the proportion of cells in the G1 stage and inhibits the expression of ADORA1, ADORA2A, and ADORA2B in short-term treatment. 7-MX has been confirmed to reduce the severity of myopia and eye elongation induced by forming deprivation in guinea pigs and to counteract the thinning of the posterior sclera and of collagen fibrils induced by form deprivation. A clinical trial showed that 7-MX reduced eye elongation and myopia progression in childhood myopia.
Status:
Investigational
Source:
NCT02451293: Phase 2/Phase 3 Interventional Completed Depression
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
5-Methoxytryptamine (aka 5-MT, mexamine) is a tryptamine derivative closely related to the neurotransmitters serotonin and melatonin. 5-MT is produced endogenously at low levels; it is biosynthesized by deacetylation of melatonin in the pineal gland. 5-MT acts as a full agonist at the 5-HT1, 5-HT2, 5-HT4, 5-HT6, and 5-HT7 receptors. It is often used as a chemical probe in the study of serotonin receptors, but it has also been used in a clinical trial to mitigate the anemic effects of cisplatin chemotherapy.
